Kineta is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Kineta has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance:
Company profile
Ticker
KANT, KANT
Exchange
Website
CEO
Mr. Craig W. Philips
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
CIGAR KING CORP, STARBERRYS CORP, VISUALANT INC, Visualant, INC
SEC CIK
Corporate docs
Subsidiaries
Kineta Operating, LLC • Kineta Chronic Pain, LLC • Yumanity, Inc. ...
KANT stock data
Latest filings (excl ownership)
25-NSE
Exchange delisting
15 Oct 24
8-K
Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors
8 Oct 24
8-K
Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
4 Oct 24
8-K
Kineta and TuHURA are collaborating on the ongoing Phase 1/Phase 2 clinical trial in patients with advance solid tumor cancer
2 Oct 24
8-K
Other Events
19 Sep 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Sep 24
8-K
Entry into a Material Definitive Agreement
13 Sep 24
8-K
Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
19 Aug 24
10-Q
2024 Q2
Quarterly report
8 Aug 24
8-K
Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences
8 Jul 24
Latest ownership filings
Financial summary
| Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 975.00 k | 975.00 k | 975.00 k | 975.00 k | 975.00 k | 975.00 k |
| Cash burn (monthly) | 291.00 k | 576.67 k | 862.67 k | 1.44 mm | 407.67 k | 794.83 k |
| Cash used (since last report) | 1.22 mm | 2.42 mm | 3.62 mm | 6.04 mm | 1.71 mm | 3.34 mm |
| Cash remaining | -247.21 k | -1.45 mm | -2.65 mm | -5.06 mm | -737.21 k | -2.36 mm |
| Runway (months of cash) | -0.8 | -2.5 | -3.1 | -3.5 | -1.8 | -3.0 |
Institutional ownership, Q2 2024
24.2% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 9 |
| Opened positions | 7 |
| Closed positions | 2 |
| Increased positions | 1 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 234.55 mm |
| Total shares | 2.96 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Raymond J. Bartoszek | 1.78 mm | $998.00 k |
| CBI USA | 721.11 k | $1.36 mm |
| PFG Investments | 326.99 k | $173.53 mm |
| Geode Capital Management | 57.76 k | $30.66 mm |
| Renaissance Technologies | 40.72 k | $21.61 mm |
| Virtu Financial | 12.94 k | $7.00 k |
| Avestar Capital | 12.00 k | $6.37 mm |
| Janney Montgomery Scott | 10.00 k | $5.00 k |
| Anfield Capital Management | 6.00 | $3.00 k |
| Proequities | 0.00 | $0.00 |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 4 Sep 24 | Raymond J. Bartoszek | Stock Option Common Stock | Grant | Acquire A | No | No | 0.611 | 12,500 | 7.64 k | 12,500 |
| 4 Sep 24 | Scott J. Dylla | Stock Option Common Stock | Grant | Acquire A | No | No | 0.611 | 12,500 | 7.64 k | 12,500 |
| 4 Sep 24 | Drapkin Kimberlee C | Stock Option Common Stock | Grant | Acquire A | No | No | 0.611 | 12,500 | 7.64 k | 12,500 |
| 4 Sep 24 | David Arkowitz | Stock Option Common Stock | Grant | Acquire A | No | No | 0.611 | 12,500 | 7.64 k | 12,500 |
| 4 Sep 24 | Peters Richard | Stock Option Common Stock | Grant | Acquire A | No | No | 0.611 | 12,500 | 7.64 k | 12,500 |
Press releases
Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024
4 Oct 24
Kineta Announces the Extension of the TuHURA Biosciences Exclusivity and Right of First Offer Agreement for KVA12123, Kineta's VISTA blocking antibody Currently in Phase 1
2 Oct 24
Kineta, Inc Transitioning from Nasdaq to OTC Markets
19 Sep 24
Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
19 Aug 24
TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer
19 Aug 24